Drug class
Non-steroidal androgen receptor (AR) antagonist; targeted antineoplastic
Mechanism of action
Binds directly to the ligand-binding domain of the androgen receptor, inhibits androgen binding and prevents AR nuclear translocation, DNA binding and AR-mediated transcription.
General use cases
- Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
- Treatment of metastatic castration-sensitive prostate cancer (mCSPC) in combination with androgen-deprivation therapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
